undamentalytics Newsletter
Sign in

Bone Biologics Corp (BBLG) stock

Add to watchlist

Add holding +

NASDAQ: BBLG Nasdaq Health Care Equipment

Bone Biologics Corp is a US-listed company in the health care equipment industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds1 adding, 2 cuttingOf 1 active managers that changed their stake, 1 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 10% in the quarter to 2026-09-30, the 2nd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 4.2% in a year, so each share owns more of the business.

Things to watch

  • Loss-making. Operating margin is -0.1%: costs exceed revenue.
  • Burning cash. Free cash flow was -0.1% of revenue over the last 12 months.
  • Volatile shares. Over the past year the shares showed annualised volatility of 65% and a beta of 1.0 against the S&P 500.
  • Missing expectations. Earnings per share fell short of the consensus estimate in 2 of the last four quarters.

Latest results: FY2021 Q2

Filed August 16, 2021
Earnings per share
-$0.17 against an average estimate of -$0.19: beat by 10.5%

Bone Biologics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.1%
  • 1 week-0.3%
  • 1 month-22.8%
  • This year-74.4%
  • 1 year-82.1%
  • 5 years-100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Shareholder vote
  2. Announcement
  3. Announcement
  4. Agreement

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Bone Biologics Corp valuation models and calculator

No model value for Bone Biologics Corp at the moment. Current status: data-quality checks not passed. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: data-quality checks not passed.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.18 +56% — 0%
Next −$0.59 +50% — 0%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +0.9% on 90 days ago. In the last 30 days, 0 analysts raised Bone Biologics Corp's forecast and 1 cut it.

Consensus EPS forecast Bone Biologics Corp, last 90 days
−$1.50 −$1.00 −$0.50 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$1.17 Current fiscal year, 60 days ago: −$1.23 Current fiscal year, 30 days ago: −$1.23 Current fiscal year, 7 days ago: −$1.23 Current fiscal year, Now: −$1.18 −$1.18 Next fiscal year, 90 days ago: −$0.64 Next fiscal year, 60 days ago: −$0.67 Next fiscal year, 30 days ago: −$0.67 Next fiscal year, 7 days ago: −$0.67 Next fiscal year, Now: −$0.59 −$0.59

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$1.17−$0.64
60 days ago −$1.23−$0.67
30 days ago −$1.23−$0.67
7 days ago −$1.23−$0.67
Now −$1.18−$0.59

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 −$0.19 −$0.17 +10.5%
Jun 2026 −$0.39 −$0.43 −10.3%
Mar 2026 −$0.54 −$0.43 +20.4%
Dec 2025 −$0.34 −$0.63 −85.3%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
0.7%
of tradable shares
Days to cover
0.08
at average volume
Short interest, 1 month
−36%
to October 15, 2026
Held by institutions
4%
of shares
Held by insiders
0.0%
of shares
Employees
2
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
BBLG−94%−91%−79%−74%−74%
Industry peers (median)−37%−8%−19%−16%−13%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
BBLG17%42%25%25%36%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
BBLG−97%−97%−86%−83%−79%
S&P 500−25%−10%−8%−19%−9%

Worst fall since October 13, 2021: 100% from November 1, 2021 to October 27, 2026. Getting back needed a 2144248% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$0.37 – $2.11
From 52-week high
−82.4%
vs 50-day average
−24.1%
vs 200-day average
−64.8%
Volatility (1 year)
65%
Beta vs S&P 500
0.96

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Fundamentals

Revenue (TTM) Bone Biologics Corp
$0 $500M $1B $1.5B FY18 Q4 FY19 Q1 FY20 Q4 FY21 Q1 FY21 Q2 Revenue (TTM), FY18 Q4: $0 Revenue (TTM), FY19 Q1: $0 Revenue (TTM), FY20 Q4: $1.1B Revenue (TTM), FY21 Q1: $1.1B Revenue (TTM), FY21 Q2: $1.1B $1.1B

Source: SEC EDGAR filings. Retrieved November 1, 2026.

View chart data
Period Revenue (TTM)
FY18 Q4 $0
FY19 Q1 $0
FY20 Q4 $1.1B
FY21 Q1 $1.1B
FY21 Q2 $1.1B

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2016 Dec 2016 2019 Dec 2019 2020 Dec 2020 LTM Jun 2021
Income
Revenue 1,070 1,070 1,070 1,070
EBITDA −20 −2 — —
Operating income −20 −2 −1 −1
Net income −26 −3 −2 −2
Diluted EPS −$297.47 −$40.53 −$54.32 —
Growth (year on year)
Revenue — 0.0% 0.0% —
Margins
EBITDA margin −1.9% −0.2% — —
Operating margin −1.9% −0.2% −0.1% −0.1%
Net margin −2.4% −0.3% −0.2% −0.2%
Free-cash-flow margin −0.7% −0.3% −0.0% −0.1%
Cash flow
Cash from operations −7 −3 −0 −1
Capital spending 0 0 0 0
Free cash flow −7 −3 −0 −1
Stock-based pay 4 0 — —
Free cash flow after stock pay −11 −3 — —
Balance sheet
Cash 1 0 — 0
Total debt 9 11 12 12
Net debt (negative = net cash) 8 11 — 12
Diluted shares — — 34m —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated BBLG TNDM INSP VREX STVN HAE Median
Revenue, last 12 months $1.1bn $1.0bn $881m $865m $1.3bn $1.4bn $102m
Revenue growth, last 12 months — 4.0% −0.2% 5.3% 12.3% 0.4% 9.2%
Revenue growth, 3-year average — 9.6% 15.6% −1.2% — 3.5% 13.5%
Revenue growth, latest quarter 0.0% 5.8% −7.9% 3.7% — 5.6% 9.9%
Gross margin — 56.0% 86.2% 34.3% 29.0% 59.0% 61.2%
Operating margin −0.1% −4.4% 1.8% 8.3% 16.8% 11.9% −8.3%
Operating margin, 3-year average — −13.9% 2.6% 3.1% — 13.6% −17.9%
Net margin −0.2% −6.1% 11.4% 2.6% 11.8% 7.1% −11.7%
Cash from operations / revenue −0.1% −0.5% 15.3% 1.3% 24.1% 24.3% −1.7%
Free-cash-flow margin −0.1% −2.6% 11.1% −2.3% 1.9% 21.5% −3.9%
Free-cash-flow margin, 3-year average — −2.9% 9.1% 2.4% — 14.3% −7.0%
Stock pay / revenue — 7.0% 13.3% 1.7% — 2.5% 6.1%
Change in share count −4.2% 3.0% −3.9% −8.8% 0.7% −6.5% 3.9%

Median of all 135 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Who owns it

Funds buying and selling
Reported value
$35,705
Institutions reporting
3
Shares held vs prior quarter
▲ 490.7%
Positions opened / closed
1 / 1

Top buyers and sellers, Q2 2026: 1 institutions bought and 2 sold ; the biggest buyer was Citadel Advisors LLC (+24K shares) and the biggest seller Tower Research Capital LLC (TRC) (−2,173). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Citadel Advisors LLC $32,714 24K 91.6% New
Tower Research Capital LLC (TRC) $2,676 2K 7.5% ▼ 52.7%
Sbi Securities Co., Ltd. $315 0K 0.9% 0.0%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Bone Biologics Corp's complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Recent SEC filings

Data status

When each part of this page on Bone Biologics Corp was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Bone Biologics Corp in brief

What does Bone Biologics Corp do?
Bone Biologics Corp is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Bone Biologics Corp's stock ticker?
Bone Biologics Corp trades under the ticker BBLG on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Bone Biologics Corp's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Citadel Advisors LLC, Tower Research Capital LLC (TRC) and Sbi Securities Co., Ltd. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Who are Bone Biologics Corp's competitors?
In our Health Care Equipment peer group, the companies closest to Bone Biologics Corp are Tandem Diabetes Care Inc, Inspire Medical Systems, Inc., Varex Imaging Corp, Stevanato Group S.p.a. and Haemonetics Corp. The side-by-side comparison below sets their revenue, margins and growth against Bone Biologics Corp's.